Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Bausch Health Companies ( (TSE:BHC) ) has provided an announcement.
Bausch Health has announced it will not proceed with the sale of its subsidiary, Bausch + Lomb, following a regulatory request and subsequent evaluation of offers that did not meet the company’s valuation expectations. Despite this, Bausch Health is committed to exploring other liability management alternatives, including raising new debt financing, and continues to focus on improving business performance, as evidenced by positive financial guidance and upcoming earnings reports.
More about Bausch Health Companies
Bausch Health Companies Inc. is a global, diversified pharmaceutical company focused on developing, manufacturing, and marketing products in areas such as gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health. The company aims to be a trusted and valued partner in the healthcare industry.
YTD Price Performance: -7.56%
Average Trading Volume: 2,117,355
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $2.71B
For an in-depth examination of BHC stock, go to TipRanks’ Stock Analysis page.
